Direct-to-Consumer Genetic Tests Should Come With a Health Warning
By Jessica Cussins,
The Pharmaceutical Journal
| 01. 15. 2015
In late 2014, the Google-backed company 23andMe announced that it would start selling its direct-to-consumer (DTC) genetic test in Canada and the UK — despite being banned by the US Food and Drug Administration (FDA) from selling it in the United States following misleading marketing.
The genetic test provides information for around 108 health conditions for which some degree of evidence exists, including 44 inherited conditions, 12 drug responses, 12 genetic risk factors and 41 traits. Some conditions on the list are both obvious and innocuous. For example, hair colour, eye colour, and height are among the 41 traits. But many of the results are about important health conditions, and are clearly supposed to incite a change in behaviour.
Genetic testing is appropriate — and can be life saving — when doctors and genetic counsellors interpret complex results and map out the various courses of action. However, DTC genetic testing companies, such as 23andME, deliberately eschew the framework between clinician and patient. Under the banner of personal empowerment, DTC companies proclaim that their products confer a new level of control over one’s health, and that...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
